Effect of early or delayed administration of warfarin with heparin on thrombosis in pulmonary thromboembolism

Medical Principles and Practice

Volumn 20, Issue 2, 2011, Pages 181-186

  Ozlu, Tevfik ^a   Aycicek, Olcay ^a   Sonmez, Mehmet ^a   Bulbul, Yilmaz ^a   Omay, Serdar Bedii ^a   Oztuna, Funda ^a   Durmus, Ahmet ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Coagulation; Heparin; Pulmonary embolism; Warfarin

Indexed keywords

D DIMER; HEPARIN; PROTEIN C; PROTEIN S; WARFARIN;

AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; FEMALE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMATOMA; HEMATURIA; HUMAN; LUNG EMBOLISM; MALE; PARTIAL THROMBOPLASTIN TIME; THERAPY DELAY; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOSIS;

AGED; ANTICOAGULANTS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMATOCRIT; HUMANS; LENGTH OF STAY; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTEIN C; PROTEIN S; PULMONARY EMBOLISM; RISK FACTORS; STATISTICS, NONPARAMETRIC; THROMBELASTOGRAPHY; TIME FACTORS; WARFARIN;

EID: 79251503642     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319767     Document Type: Article

References (17)

1. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21: 1301-1336.
2. Hirsh J, Hoak J: Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 1996; 93: 2212-2245.
3. Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; ii:1293-1296.
4. Mohiuddin SM, Hilleman DE, Destache CJ, Stoysich AM, Gannon JM, Sketch MH Sr: Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. Am Heart J 1992; 123: 729-732.
5. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264.
6. Leroyer C, Bressollette L, Oger E, Mansourati J, Chèze-Le Rest C, Nonent M, Buchmuller A, Tardy B, Decousus H, Parent F, Simonneau G, Juste K, Ill P, Abgrall JF, Clavier J, Mottier D: Early versus delayed introduction of oral vitamin K antagonists in combination with low-molecular-weight heparin in the treatment of deep vein thrombosis. a randomized clinical trial. The ANTENOX Study Group. Haemostasis 1998; 28: 70-77.
7. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D, Brandt JT: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 445S-469S.
8. Weiss P, Soff GA, Halkin, Seligsohn U: Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 1987; 45: 783-790.
9. Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H, Miyata T: Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 1995; 15: 241-246.
10. Camou F, Viallard JF, Caubet O, Pellegrin JL: Thrombocytosis: adverse effect of heparin treatment. Presse Med 2006; 35: 58-60.
11. Hummel MC, Morse BC, Hayes LE: Reactive thrombocytosis associated with enoxaparin. Pharmacotherapy 2006; 26: 1667-1670.
12. Liautard C, Nunes AM, Vial T, Chatillon F, Guy C, Ollagnier M, Deseotes J: Low-molecular-weight heparins and thrombocytosis. Ann Pharmacother 2002; 36: 1351-1354.
13. Kakkasseril JS, Cranley JJ, Panke T, Grannan K: Heparin-induced thrombocytopenia: a prospective study of 142 patients. J Vasc Surg 1985; 2: 382-384.
14. Cooney MF: Heparin-induced thrombocytopenia: advances in diagnosis and treatment. Crit Care Nurse 2006; 26: 30-36.
15. Franchini M: Heparin-induced thrombocytopenia: an update. Thromb J 2005; 3: 14.
16. Mureebe L, Silver D: Heparin-induced thrombocytopenia: pathophysiology and management. Vasc Endovascular Surg 2002; 36: 163-170.
17. Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Rainirez-Lassepas M: Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther Drug Monit 1983; 5: 205-211.